Estimating direct costs of the treatment for mucosal leishmaniasis in Brazil.

摘要: INTRODUCTION The objective of this study was to estimate the direct medical costs treatment for mucosal leishmaniasis (ML) using three therapeutic approaches in Brazilian context. METHODS We performed economic assessment from perspective public healthcare system. following were evaluated: meglumine antimoniate, liposomal amphotericin B, and miltefosine. Direct estimated considering four components: a) drug, b) combined products, c) procedures, d) complementary tests. RESULTS Treatment with antimoniate had lowest average cost per patient (US$ 167.66), followed by miltefosine 259.92) outpatient regimen. B US$ 715.35 both inpatient In all estimates, drugs accounted more than 60% total each approach. CONCLUSIONS These results demonstrate marked differences between alternatives ML. addition efficacy rates related adverse events, our data have potential support a complete cost-effectiveness future. Complete analyses comparing benefits interventions will assist health managers choosing ML Brazil as well establishing effective policies.